Germany- based Merck has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMEA) for Cladribine Tablets, an investigational oral formulation of cladribine, for patients with
Roche posts sales figure of CHF24,006m for the six month ended period, 2009. Net income for the company was CHF4,051m, a decrease of 29% compared to the previous
Thermo Fisher Scientific has reported that revenues decreased 8% to $2.48 billion in the second quarter of 2009, compared with $2.71 billion in the 2008 quarter. GAAP diluted
miRagen and Archemix will collaborate on conjugated aptamer-microRNA therapies. miRagen and Archemix to jointly pursue R&D efforts and contribute resources under the agreement. It includes an exclusive option
Rigel has reported that in the TASKi3 phase 2b clinical trial in rheumatoid arthritis (RA) study, has failed to meet its efficacy endpoints. Reportedly, the patients who had
FDA has approved a new use for Eli Lilly’s osteoporosis drug – Forteo [teriparatide (rDNA origin) injection]. The drug is to treat osteoporosis associated with sustained, systemic glucocorticoid
Germany-based, Merck has announced a steady group total revenues in the second quarter and in the first half of 2009 at E1902m and E3756m respectively. Company also posts
The company’s net income and diluted earnings per share for the 2009 second quarter were $1.27 billion and $0.94 respectively, as compared to $1.12 billion and $0.83 respectively,
QRxPharma has initiated a phase 2 comparative proof-of-concept study to evaluate the efficacy and safety of MoxDuo IV (intravenous morphine and oxycodone) versus IV morphine alone. It is
Open Monoclonal Technology (OMT), in collaboration with Sangamo BioSciences, Sigma-Aldrich, Medical College of Wisconsin, and INSERM, has created the first targeted knockout rats as detailed in Knockout Rats
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.